Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 13Sarcoma 8Genitourinary 2Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 84Kidney Neoplasms 22Prostatic Neoplasms 14Neoplasm Metastasis 10Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Hepatocellular 5Liver Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Sarcoma 2Multiple Myeloma 2Hematologic Neoplasms 2Glioblastoma 2Financial Stress 2Wilms Tumor 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Bevacizumab 5pembrolizumab 3Paclitaxel 3fludarabine 2Sorafenib 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1erythromycin propionate-N-acetylcysteinate 1durvalumab 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1belzutifan 1aflibercept 1abiraterone 1Thalidomide 1Temozolomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × Sorafenib × Genitourinary × Clear all
NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡